Physician profile
Brian Yum
NPI 1326572231
$13,389.76
in general payments reported to CMS, 2019-2025
34 companies · $90.26 in 2025
The $90.26 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2021: $1,527 · 2022: $3,234 · 2023: $6,072 · 2024: $2,466 · 2025: $90.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,246 · Travel and Lodging: $3,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,246.11 |
| Travel and Lodging | $3,381.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,954.56 | 2021-2025 | Ensite Precision, Supera, Mitraclip |
| Medtronic, INC. | $768.86 | 2021-2024 | Corevalve Evolut R, Cobalt Dr Mri Surescan, Azure Xt Dr Mri Surescan |
| Actelion Pharmaceuticals US, INC. | $621.26 | 2021-2025 | Uptravi, Opsumit |
| Inari Medical, INC. | $595.84 | 2021-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boston Scientific Corporation | $585.24 | 2021-2023 | Versacross Access Solution |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $522.99 | 2021-2025 | Lifevest |
| Angiodynamics, INC. | $458.13 | 2022-2024 | Alphavac |
| Pfizer INC. | $381.77 | 2021-2024 | |
| Abiomed | $375.16 | 2021-2022 | |
| Edwards Lifesciences Corporation | $360.79 | 2022-2024 | |
| Biosense Webster, INC. | $355.69 | 2022-2023 | Carto 3 |
| Cardiva Medical, INC. | $338.40 | 2022-2024 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs, Savvywire |
| Amgen INC. | $309.19 | 2021-2024 | Repatha |
| Teleflex LLC | $308.00 | 2021-2024 | Trapliner |
| Sanofi-Aventis U.S. LLC | $263.44 | 2022-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $251.68 | 2021-2023 | |
| Esperion Therapeutics, INC. | $239.58 | 2021-2022 | |
| W. L. Gore & Associates, INC. | $239.30 | 2021-2023 | Gore Cardioform Septal Occluder |
| Astrazeneca Pharmaceuticals Lp | $184.78 | 2021-2024 | Wainua, Farxiga |
| Heartflow, INC. | $172.76 | 2024-2025 | |
| Impulse Dynamics (USA) INC. | $156.28 | 2022-2023 | Optimizer |
| Livanova USA, INC. | $151.69 | 2023 | Tandemheart |
| Janssen Pharmaceuticals, INC | $132.93 | 2021-2024 | Xarelto |
| Astellas Pharma US INC | $122.69 | 2021 | |
| Philips North America LLC | $111.36 | 2023 | |
| Terumo Medical Corporation | $104.35 | 2022 | |
| Shockwave Medical, INC | $81.31 | 2022-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.49 | 2022-2024 | Jardiance |
| Kiniksa Pharmaceuticals, Ltd. | $40.94 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $32.56 | 2024 | Arcalyst |
| Cvrx, INC. | $28.79 | 2024 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $27.35 | 2023 | Inpefa |
| Cordis US Corp. | $24.37 | 2023 | Outback Elite |
| Chiesi USA, INC. | $16.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$207.49 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Yum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.